ADITUM
Enrich your Research

Clinical Medical Case Reports and Case Series

Opinion Article

Toll-like-Receptor and Takeda-G-Protein-Receptor-5 Interplay in Immunomodulation of Inflammatory Colorectal Cancer and Cholangiocarcinomas: Cancer-Immunotherapy Snapshot

Saumya Pandey
M. Sc. Biochemistry, Ph.D. Life Science, Post-Doctoral Fellowship: Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas/Doctoral Research Fellowship: Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska/Visiting Scientist-Clinical Observer: Urology, New York Presbyterian-Weill Cornell Medical College, New York, NY, USA and Department of Clinical Research, IndiraIVF Hospital, Udaipur/Lucknow, India (Formerly).

Article Info

Received: August 07, 2024
Accepted: August 19, 2024
Published: August 22, 2024

***Corresponding author:** Saumya Pandey, M.Sc. Biochemistry, Ph.D. Life Science, Post-Doctoral Fellowship: Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas/Doctoral Research Fellowship: Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska/Visiting Scientist-Clinical Observer: Urology, New York Presbyterian-Weill Cornell Medical College, New York, NY, USA and Department of Clinical Research, IndiraIVF Hospital, Udaipur/Lucknow, India (Formerly).

Citation: Saumya Pandey. (2024) "Toll-like-Receptor and Takeda-G-Protein-Receptor-5 Interplay in Immunomodulation of Inflammatory Colorectal Cancer and Cholangiocarcinomas: Cancer-Immunotherapy Snapshot.", Clinical Medical Case Reports and Case Series, 1(1); DOI: 10.61148/ CMCRCS/004

Abstract:

Dissecting the cellular/molecular/genetic regulatory biochemical immune-inflammatory signaling networks, primarily Toll-like-Receptor and Takeda-G-Protein-Receptor-5 intersections in "gastrohepatic disease-web" primarily colorectal/cholangio-carcinomas, is essential for diminishing the disproportionate share of morbidities and mortalities in susceptible "at-risk" American cohorts of Texas, Nebraska and New York states in USA and Indian cohorts in Asia-Pacific region for eventual design of promising evidence-based patient-friendly cost-effective predictive and prognostic biomarkers and/or pharmacological scaffolds for future immune-therapeutically potent drugs with minimal adverse effects in the post-Covid-19/Omicron global pandemic and vaccination era.

Aberrant "metabolic-flux" in the hypoxic/vascular-insufficient/inflammatory heterogeneous tumour-core infiltrated with proliferative and/or necrotic/apoptotic/autophagic cells of distinct phenotypes, is a major hallmark of gastro-hepatic-cancers; therapeutic targeting of "immunogenic cell-death cascade(s)" viz. autophagy-necrosis-apoptosis, offers fascinating avenues for future stem cells'-translational research in the Covid-19 pandemic era.

Pandey [4] has elegantly emphasized the significance of age-/ethnicity-matched disease-free controls from the general random population in multi-centric epidemiology/ pharmacogenetics/genomics studies for demystifying the cellular/molecular/genetic basis of inflammatory gastro-hepatic ailments in susceptible cohorts. Moreover, receptor-based heterogeneity of ghrelin is indeed intriguing wherein a single ghrelin receptor and/or interrelated co-receptor may have differential binding affinity, leading to altered metabolic flux in the host cell and tissue in aberrant physiologic mileu in the inflammatory gastric epithelium.

Future multi-centric large sample size-based case–control prospective studies adhering to core tenets of good practice ethical research with long-term patient satisfaction trends are warranted for precision-based novel Toll-like-Receptor and Takeda-G-Protein-Receptor-5 immunotherapeutics in colorectal/cholangio-carcinomas.

Conflicts of interest:

The author declares that she has no conflicts of interest and financial disclosures.

References:

1. Pandey S, Agrawal DK. Immunobiology of Toll-like Receptors: Emerging trends. Immunology and Cell Biology 2006; 84(4):333-341.
2. Pandey S. Re: Takeda-G Protein Receptor-5 signaling mitigates parenteral nutrition-associated liver disease: Public health impact. American Journal of Physiology Gastrointestinal Liver Physiology 2020; 318(5):G928-G929.
3. Kouroumalis E, Tsomidis I, Voumvouraki A. Interplay of autophagy, apoptosis, and senescence in primary biliary cholangitis. Explor Dig Dis. 2023;2:223–45.
4. Pandey S. Letter to Editor: Healthy Controls in Non-Alcoholic Fatty Liver Disease Management: a Biomedical Research Perspective. Hepatology 2017; 66(3):1006-1007.